Hypothalamic amenorrhea in mid-adulthood linked to heart disease
Mid-adulthood functional hypothalamic amenorrhea was linked to a 62% higher cardiovascular disease risk and an HR of 1.91 for coronary heart disease compared to regular cycles.
The Journal of Clinical Endocrinology and Metabolism
In a prospective study of 52,655 premenopausal women from the Nurses' Health Study II, researchers assessed whether a functional hypothalamic amenorrhea (FHA) phenotype was linked to incident cardiovascular disease. Participants were free of cardiovascular disease in 1993 and followed biennially through 2019, recording 1,007 cardiovascular events over up to 26 years. The FHA phenotype was defined as irregular or absent cycles without polycystic ovary syndrome traits, paired with low body mass index or high physical activity. Compared with regular cycles, FHA in mid-adulthood was associated with a 62% higher risk of cardiovascular disease and a higher risk of coronary heart disease (HR = 1.91). FHA was also linked to type 2 diabetes (HR = 1.86), but not hypertension or elevated cholesterol. FHA in early adulthood was not associated with outcomes.
Why it matters
The findings suggest that specific reproductive endocrine disruptions during midlife may serve as an early indicator of cardiometabolic and vascular aging in women.
Caveats
As an observational study, the analysis cannot determine causality, and the amenorrhea phenotype relied on surrogate lifestyle and menstrual cycle definitions rather than clinical hormone workups.
- Functional hypothalamic amenorrhea
- Cardiovascular disease
- Coronary heart disease
- Type 2 diabetes
- Hypertension
- Humans
The paper
Functional Hypothalamic Amenorrhea Phenotype and Cardiovascular Disease Risk
Show 7 more authors
Xiaoyu Che, JoAnn E Manson, Karen K Miller, Kathy Rexrode, Stephanie Faubion, Sarah Berga, C Noel Bairey Merz,Women's Health Research Center and Division of General Internal Medicine · Harvard T. H. Chan School of Public Health
The Journal of Clinical Endocrinology and Metabolism · 5 Oct 2026